Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma

NCT07686575 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT07686575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07686575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
Lead sponsor
Zhujiang Hospital
Phase
Observational
Overall status
Recruiting
Start date
January 26, 2026
Completion date
August 30, 2028
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hnscc, ivonescimab, opscc, oscc